Secukinumab - Biologic Drug Details

Summary for secukinumab

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for secukinumab

Recent Clinical Trials for secukinumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
BioRay Pharmaceutical Co., Ltd.	Phase 1
Assiut University	Phase 1
Qilu Hospital of Shandong University	Phase 4

See all secukinumab clinical trials

Pharmacology for secukinumab

Mechanism of Action	Interleukin-17A Antagonists
Established Pharmacologic Class	Interleukin-17A Antagonist

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for secukinumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for secukinumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for secukinumab Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for the Biologic Drug: Secukinumab

Introduction

Secukinumab, marketed under the brand name Cosentyx, is a human IgG1κ monoclonal antibody developed by Novartis for the treatment of various autoimmune and inflammatory diseases, including psoriasis, ankylosing spondylitis, psoriatic arthritis, and recently approved for hidradenitis suppurativa (HS). Here, we delve into the market dynamics and financial trajectory of secukinumab.

Market Approval and Adoption

Secukinumab was first approved in 2015 for the treatment of moderate to severe plaque psoriasis and has since expanded its indications to include other autoimmune diseases. The recent approval for HS in October 2023 marks a significant milestone, showcasing its growing acceptance in clinical practice[1].

Increasing Awareness and Prescription Rates

Among US dermatologists, there has been a steady rise in awareness and prescription rates for secukinumab. A survey by Spherix Global Insights revealed that 59 out of 76 dermatologists surveyed are actively prescribing secukinumab, indicating a strong foothold in the HS treatment landscape[1].

Comparative Performance

Secukinumab has garnered positive perceptions from dermatologists regarding its clinical benefits. However, it faces competition from established treatments like adalimumab (Humira). Despite challenges related to out-of-pocket costs and ease of access, where adalimumab holds an edge, secukinumab's sustained efficacy and overall performance continue to drive its adoption[1].

Financial Performance

The financial trajectory of secukinumab has been robust. In 2018, Cosentyx drove a 5% increase in Novartis' net sales, reaching $51.9 billion. The drug saw strong volume growth across all indications in the US and EU, with sales growing by 34% in the US and 32% in the rest of the world[2].

Market Growth Projections

The global IL-17 biologics market, which includes secukinumab, is expected to expand significantly. By 2030, this market is projected to reach $10.9 billion, up from $4.37 billion in 2022, with a compound annual growth rate (CAGR) of 12.3% from 2024 to 2030[3].

Regional Market Dynamics

North America is anticipated to dominate the market with a significant share, driven by a large population suffering from autoimmune disorders and comprehensive health plan coverage for expensive biologic drugs like Cosentyx. The Asia Pacific region is also emerging as a key market due to rising disease prevalence and increasing affordability of biologic treatments in developing economies like China and India[4].

Challenges and Opportunities

One of the major challenges for secukinumab is the impending patent expiry in 2027, which could lead to the introduction of biosimilar versions and increased competition. However, geographic expansion into emerging markets presents a significant opportunity. Patient support programs, including financial assistance and educational resources, have enhanced patient adherence and overall satisfaction with IL-17 biologics, further driving market growth[3][4].

Cost-Effectiveness

Studies have shown that secukinumab is cost-effective, particularly for patients who have responded inadequately to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). For example, in the UK, secukinumab has been found to have an incremental cost-effectiveness ratio (ICER) of £28,748 per quality-adjusted life year (QALY) gained compared to standard of care, making it a valuable use of NHS resources[5].

Impact of Macro Economic Factors

The COVID-19 pandemic has had various impacts on the biologics market, but the demand for innovative treatments like secukinumab has remained strong. The pandemic has highlighted the importance of effective treatments for autoimmune and inflammatory diseases, further propelling the growth of the IL-17 biologics market[3].

Pipeline Development and Future Prospects

The pipeline for IL-17 biologics is robust, with ongoing research and development aimed at improving efficacy and safety profiles. This continuous innovation is crucial for maintaining market share and addressing the evolving needs of patients. As dermatology clinicians become more familiar with the benefits of secukinumab, its adoption is expected to increase, driven by sustained efficacy and positive impact on patient quality of life[1][3].

Key Takeaways

• Growing Awareness and Adoption: Secukinumab has seen increased awareness and prescription rates among dermatologists.
• Financial Performance: The drug has driven significant revenue growth for Novartis.
• Market Projections: The global IL-17 biologics market is expected to expand at a CAGR of 12.3% from 2024 to 2030.
• Regional Dynamics: North America and the Asia Pacific region are key markets.
• Challenges and Opportunities: Patent expiry and biosimilar competition are challenges, while geographic expansion and patient support programs offer opportunities.
• Cost-Effectiveness: Secukinumab is cost-effective for patients who have responded inadequately to conventional treatments.

FAQs

Q: What is secukinumab used for? A: Secukinumab is used for the treatment of various autoimmune and inflammatory diseases, including psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa.

Q: How has the market adoption of secukinumab been since its approval for HS? A: Since its approval for HS in October 2023, secukinumab has seen a steady rise in awareness and prescription rates among US dermatologists.

Q: What are the main challenges facing secukinumab in the market? A: The main challenges include out-of-pocket costs, ease of access compared to competitors like adalimumab, and the impending patent expiry in 2027.

Q: How cost-effective is secukinumab compared to other treatments? A: Secukinumab has been found to be cost-effective, particularly for patients who have responded inadequately to conventional treatments, with an ICER of £28,748 per QALY gained in the UK.

Q: What are the future prospects for the IL-17 biologics market? A: The global IL-17 biologics market is expected to grow at a CAGR of 12.3% from 2024 to 2030, reaching $10.9 billion by 2030.

Sources

1. Spherix Global Insights, "Evaluating the Efficacy and Perception of HS Treatment Options," Dermatology Times, October 31, 2023.
2. PharmaTimes, "Cosentyx demand helps drive Novartis' net sales up 5% in 2018," PharmaTimes, 2018.
3. Business Wire, "Global IL-17 Biologics Market Research Report 2023," ResearchAndMarkets.com, 2023.
4. Coherent Market Insights, "Cosentyx Drug Market Size & Share Analysis - Growth Trends," Coherent Market Insights, 2024.
5. PMC, "Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis," PMC, May 25, 2018.

Last updated: 2024-12-17